Remove Insulin Remove Medicine Remove Pharmacy
article thumbnail

Opinion: Even with lawsuits and copay caps, will insulin ever be affordable?

STAT News

In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin. The sausage-making of how insulin is priced is not for the faint of heart.

Insulin 105
article thumbnail

Eli Lilly Partners with Amazon Pharmacy for Home Delivery of Drugs

XTalks

LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).

Pharmacy 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Illegal online pharmacies gain traction as regulators lag behind

Pharmaceutical Technology

The FDA has flagged this issue as pharmacies selling prescription drugs illegally have proliferated over the years. However, a growing number of illegitimate online pharmacies are avoiding established pathways that require prescriptions to provide medicines.

Pharmacy 130
article thumbnail

STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing

STAT News

The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers of fixing prices for various medicines, the latest effort to scrutinize the controversial companies that occupy a crucial role in pharmaceutical pricing.

Pharmacy 111
article thumbnail

STAT+: Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs

STAT News

… UnitedHealth Group’s pharmacy benefits manager, OptumRx, will keep AbbVie’s Humira alongside up to three biosimilar medicines next year, Bloomberg News writes. pharmacy benefit manager and managed $112 billion in drug spending last year, will place biosimilars on its formulary in the same position as Humira.

Insulin 96
article thumbnail

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

The Pharma Data

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52
article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

It is all about what you can get at the lowest cost,” says Dr. Raymond Cross, director of the inflammatory bowel disease program at University of Maryland’s School of Medicine, Baltimore. For example, the first-to-market status was beneficial when it came to insulin biosimilars. …[but] for biosimilars, it is all about the money.

Marketing 262